NasdaqGM - Delayed Quote USD

I-Mab (IMAB)

1.8700

-0.0300

(-1.58%)

At close: June 6 at 4:00 PM EDT

I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team.

PR Newswire 14 hours ago

AZN

AZNCF

IMAB
-1.58%
I-Mab and BMS assess givastomig for gastric and oesophageal cancer

Givastomig targets CLDN18.2 on tumour cells and activates T-cells at the tumour site.

Pharmaceutical Technology 16 hours ago

IMAB
-1.58%
CELG-RT
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers

I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that it has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY). The collaboration will evaluate the combination of givastomig, an investigational Claudin 18.2 x 4-1BB bispecific antibody jointly developed by I-Mab a

PR Newswire yesterday

IMAB
-1.58%
I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024

Encouraging objective responses were observed in heavily pre-treated patients, including 1 complete response (CR) and 6 partial responses (PR), mainly in patients previously treated with checkpoint inhibitorsPhase 1 dose-escalation data demonstrated that ragistomig monotherapy can be safely administered through the highest planned doses Data will be presented at the 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO2024) in a poster session scheduled for June 1, 2024 at 9:00

GlobeNewswire 14 days ago

IMAB
-1.58%
I-Mab to Participate at the Jefferies Global Healthcare Conference

I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the Jefferies Global Healthcare Conference on June 5, 2024.

PR Newswire 15 days ago

IMAB
-1.58%
Q1 2024 Summit Therapeutics Inc Earnings Call

Q1 2024 Summit Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents last month

SMMT

IMAB
-1.58%
I-MAB Filed 2023 Annual Report on Form 20-F

I-Mab (the "Company") (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that it has filed its annual report on Form 20-F for the year ended December 31, 2023 with the U.S. Securities and Exchange Commission ("SEC") on April 30, 2024.

PR Newswire last month

IMAB
-1.58%
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference on April 11, 2024.

PR Newswire 2 months ago

IMAB
-1.58%
I-Mab Announces Closing of the Divestiture of Business Operations in China

I-Mab (the "Company") (NASDAQ: IMAB) a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that all conditions precedent to the divestiture transaction previously announced on February 7, 2024 (the "Transaction") have been either satisfied or waived and accordingly, the Transaction has successfully closed.

PR Newswire 2 months ago

IMAB
-1.58%
I-Mab Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

I-Mab ( NASDAQ:IMAB ) Full Year 2023 Results Key Financial Results Net loss: CN¥1.47b (loss narrowed by 39% from FY...

Simply Wall St. 2 months ago

IMAB
-1.58%
I-Mab Reports Full Year 2023 Financial Results and Business Update

I-Mab (the "Company") (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced financial results for the full year ended December 31, 2023, and highlighted recent business updates.

PR Newswire 2 months ago

IMAB
-1.58%
Q4 2023 Summit Therapeutics Inc Earnings Call

Q4 2023 Summit Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents 3 months ago

SMMT

IMAB
-1.58%
UPDATE 2-Biotech firm I-Mab to divest China operations, shift focus to US

I-Mab said on Wednesday it has agreed to divest its operations and assets in China as part of its strategy to become a U.S.-focused biotech firm, sending the company's shares up nearly 11% in premarket trading. The company will sell its China unit, I-Mab Shanghai, to affiliate Hangzhou Co for up to $80 million, subject to certain regulatory and sales-based milestones. The move makes strategic sense, Cantor Fitzgerald analyst Louise Chen said, adding that the development came as a surprise.

Reuters 3 months ago

IMAB
-1.58%
I-Mab Signs Agreement to Divest its Assets and Business Operations in China

I-Mab (the "Company") (NASDAQ: IMAB), a global biotech company exclusively focused on bringing highly differentiated immunotherapies and biologics for cancer treatment to patients around the world, today announced that as part of its strategy to become a U.S.-based biotech, its Chinese subsidiaries have entered into definitive agreements with I-Mab Biopharma (Hangzhou) Co., Ltd. (the "Hangzhou Company"), an unconsolidated affiliate of the Company, and a group of China-based investors to divest t

PR Newswire 3 months ago

IMAB
-1.58%
Individual investors account for 41% of I-Mab's (NASDAQ:IMAB) ownership, while private equity firms account for 26%

Key Insights The considerable ownership by individual investors in I-Mab indicates that they collectively have a...

Simply Wall St. 6 months ago

IMAB
-1.58%
I-Mab Announces Participation at Jefferies and Piper Conferences in November

I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, today announced its in-person participation in two conferences in November 2023, the Jefferies London Healthcare Conference and the Piper Sandler 35th Annual Healthcare Conference. Details of the conferences and management presentation are as follows:

PR Newswire 6 months ago

IMAB
-1.58%
Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)

I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, and HI-Bio, a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BT

PR Newswire 7 months ago

IMAB
-1.58%
I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023

I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, today announced that two poster presentations featuring preclinical data on givastomig (also known as TJ-CD4B/ABL111) and TJ-L14B/ABL503, the Company's 4-1BB-targeting bispecific antibody assets, will be reported at the 38th Society for Immunotherapy o

PR Newswire 7 months ago

IMAB
-1.58%
I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023

I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, today announced that the updated clinical results from its Phase 1 study of givastomig (also known as TJ-CD4B/ABL111) in advanced solid tumors will be reported in a poster presentation at the upcoming European Society for Medical Oncology (ESMO) Congre

PR Newswire 7 months ago

IMAB
-1.58%
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503

I-Mab (Nasdaq: IMAB) (the "Company"), a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics, today announced multiple recent developments in TJ-L14B/ABL503, a differentiated PD-L1 x 4-1BB bispecific antibody developed in collaboration with ABL Bio (Kosdaq: 298380). TJ-L14B/ABL503 is designed to address tumors resistant to PD-(L)1 antibodies th

PR Newswire 7 months ago

IMAB
-1.58%

Performance Overview

Return	IMAB	MSCI WORLD
YTD	-1.58%	+10.15%
1-Year	-43.33%	+21.30%
3-Year	-97.60%	0.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

I-Mab (IMAB)

I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

I-Mab and BMS assess givastomig for gastric and oesophageal cancer

I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers

I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024

I-Mab to Participate at the Jefferies Global Healthcare Conference

Q1 2024 Summit Therapeutics Inc Earnings Call

I-MAB Filed 2023 Annual Report on Form 20-F

I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference

I-Mab Announces Closing of the Divestiture of Business Operations in China

I-Mab Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

I-Mab Reports Full Year 2023 Financial Results and Business Update

Q4 2023 Summit Therapeutics Inc Earnings Call

UPDATE 2-Biotech firm I-Mab to divest China operations, shift focus to US

I-Mab Signs Agreement to Divest its Assets and Business Operations in China

Individual investors account for 41% of I-Mab's (NASDAQ:IMAB) ownership, while private equity firms account for 26%

I-Mab Announces Participation at Jefferies and Piper Conferences in November

Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)

I-Mab Announces Poster Presentations of 4-1BB Bispecific Antibody Portfolio at SITC 2023

I-Mab Announces Phase 1 Data of Givastomig at ESMO 2023

I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503

Performance Overview